Noncontrolling Interest (Tables)

12 Months Ended

Dec. 31, 2021

Noncontrolling Interest [Abstract]

Schedule of Noncontrolling Interest of Stockholders' Equity

The noncontrolling interest (“NCI”) included as a component of consolidated total stockholders’ equity is summarized for the periods indicated as follows:

	Year Ended December 31,
	2021			2020
NCI – equity (deficit) – beginning of period	$	(2,369	)	$	(814	)
Investment in Veris Health Inc.		6			—
Net loss attributable to NCI – Lucid Diagnostics Inc.		(5,280	)		(1,503	)
Net loss attributable to NCI – Solys Diagnostics Inc.		(34	)		(109	)
Net loss attributable to NCI – Veris Health Inc.		(465	)		—
Impact of subsidiary equity transactions		16,760			—
Lucid Diagnostics Inc. 2018 Equity Plan stock option exercise		—			5
Stock-based compensation expense - Lucid Diagnostics Inc. 2018 Equity Plan		9,134			52
NCI – equity (deficit) – end of period	$	17,752		$	(2,369	)